1. Belgium Stocks

  2. •

    Process industries

  3. •

    Chemicals: agricultural
Biotalys NV

Biotalys NV

1.65
EUR
-0.02
(-1.43%)
140.65MMarket Cap
Mar 05Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.26
-0.36
-1.1
-0.74
-0.65
-0.4
-0.42
- -
Free Cash Flow per Basic Share
- -
-0.3
-0.45
-1.17
-0.67
-0.59
-0.38
-0.37
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.7
0.85
1.91
1.23
0.8
0.74
0.32
0.33
Tangible Book Value per Share
0.05
0.68
0.83
1.89
1.21
0.78
0.72
0.31
0.32
Basic Weighted Avg Shares
30
30
30
15
31
32
33
37
38
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
1
1
2
2
2
2
- -
Net Income, GAAP
- -
-8
-11
-17
-23
-21
-13
-16
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
18
19
54
32
19
21
7
10
LT Debt
1
1
4
6
5
5
4
3
2
Total Equity
2
21
26
59
38
26
28
12
15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-65.86
-46.02
-40.04
-46.85
-64.41
-49.6
-79.37
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
38
45
Market Capitalization
179
127
141

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
19
11
16
Cash, Cash Equivalents & STI
18
8
14
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
5
5
5
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2.66%
-56.16%
Free Cash Flow
- -
3.21%
8.37%
Net Income, GAAP
- -
13.15%
19.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.4
2025
- -
- -
-0.42
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carlo Boutton
Full Time Employees
62
Sector
Process industries
Industry
Chemicals: agricultural
Address
Buchtenstraat 11 Ghent Belgium 9051
IPO Date
Jul 2, 2021
Website
biotalys.com
Similar Companies
UPL Limited (NSE:UPL)
Mosaic Company (The) (NYSE:MOS)
CF Industries Holdings, Inc. (NYSE:CF)
PhosAgro (MOEX:PHOR)
Abou Kir Fertilizers & Chemical Industries Co. (EGX:ABUK)
Misr Fertilizers Production Company MOPCO (EGX:MFPC)
Business
Biotalys N.V. (Euronext Brussels: BTLS.BR) develops protein-based biocontrol solutions for sustainable crop protection as an agricultural technology company targeting pests and diseases across the food value chain from soil to plate. The company offers a pipeline of products based on its proprietary AGROBODY™ technology platform, including the lead biofungicide EVOCA™ against botrytis and powdery mildew in fruits and vegetables, which received U.S. EPA regulatory approval in 2025 and awaits EU approval; EVOCA NG, an enhanced next-generation formulation with planned U.S. registration in 2028-29; BioFun-6 targeting additional fungal pathogens; and BioFun-8, a new biofungicide program launched in October 2024 against Alternaria leaf spot in fruits, vegetables, and potatoes, addressing a USD 1.1 billion market opportunity; as well as earlier-stage bioinsecticides and biobactericides. Biotalys serves pre- and post-harvest markets for growers seeking alternatives to chemical pesticides with novel modes of action, low environmental impact, and favorable safety profiles. Founded in 2013 as a spin-off from VIB (Flanders Institute for Biotechnology), the company maintains headquarters in Ghent, Belgium, with a North American subsidiary office in North Carolina, USA, and recently opened expanded R&D facilities there comprising 1,800 square meters of laboratory space. Recent developments include a EUR 15 million private placement in October 2024 with new investor ASR Vermogensbeheer and existing backers Ackermans & van Haaren and AIF to fund regulatory processes for EVOCA™ and EVOCA NG, field trials for BioFun-6, and pipeline expansion; addition of BioFun-8 to the R&D pipeline in 2024; a strategic partnership announced in May 2025 with AgroFresh Solutions, Inc. for post-harvest biological solutions; and ongoing academic collaborations for programs like BioFun-4.